Impact of programmed death ligand 1(PDL1) on prognosis of adult acute myeloid leukaemia (AML) patients

Abstract

PD1/PD-L1 pathway is an immune checkpoint pathway that has been incriminated in the pathogenesis as well as the progression of so many solid tumours and hematologic malignancies including malignant melanoma and Hodgkin’s disease. The aim of this study was to assess PD-L1 expression in patients with acute myeloid leukemia as the primary aim. The secondary aim was to relate its expression to different patients’ and disease characteristics, prognostic factors, treatment outcome as well as patients’ survival. To achieve this, a total number of 40 adult newly diagnosed cases of denovo AML has been recruited from the Clinical Hematology and Oncology Division, Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. PD-L1 expression has been measured on the surface of blast cells using flowcytometric analysis.